SLB OneSubsea Awarded EPC Contract for Equinor’s Fram Sør Project
Subsea electrification enables large-scale tieback solution in the North Sea
Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded an engineering, procurement and construction (EPC) contract by Equinor for a 12-well, all-electric Subsea Production System (SPS) in the Fram Sør field, offshore Norway.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250825924465/en/

SLB OneSubsea will deliver 4 subsea templates and 12 all-electric subsea trees, eliminating the need for hydraulic fluid supplied by the host platform and keeping topside modifications to a minimum.
The award follows a collaborative, year-long Front-End Engineering Design phase, where Equinor and SLB OneSubsea jointly matured the project, culminating in the development plan and final investment decision (FID). As part of the resulting EPC scope, SLB OneSubsea will deliver four subsea templates and 12 all-electric subsea trees, eliminating the need for hydraulic fluid supplied by the host platform and keeping topside modifications to a minimum. This approach unlocks a cost-effective solution for the project while retaining topside space for additional, future expansion projects in the area.
“Fram Sør is a breakthrough project for our industry — marking the first large-scale all-electric subsea production system,” said Mads Hjelmeland, chief executive officer of SLB OneSubsea. “Not only do all-electric subsea solutions significantly reduce topside needs to make large-scale tiebacks such as the Fram Sør development possible, but they also hold the key to unlock more marginal resources through their reduced footprint and simplified operations.”
The project will be developed as a subsea tieback to the host platform Troll C in the North Sea, contributing to the security of energy supply from the Norwegian continental shelf (NCS) to Europe. Benefitting from a host that is powered from Norwegian shores, the production from Fram Sør will have very low emissions.
The contract is subject to regulatory approval of the plan for development and operations (PDO).
About SLB
SLB (NYSE: SLB) is a global technology company that drives energy innovation for a balanced planet. With a global footprint in more than 100 countries and employees representing almost twice as many nationalities, we work each day on innovating oil and gas, delivering digital at scale, decarbonizing industries, and developing and scaling new energy systems that accelerate the energy transition. Find out more at slb.com.
About SLB OneSubsea
SLB OneSubsea is driving the new subsea era that leverages digital and technology innovation to optimize our customers’ oil and gas production, decarbonize subsea operations and unlock the large potential of subsea solutions to accelerate the energy transition. OneSubsea is a joint venture backed by SLB, Aker Solutions and Subsea7 headquartered in Oslo and Houston, with 10,000 employees across the world. Find out more at onesubsea.com.
Cautionary Statement Regarding Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws — that is, statements about the future, not about past events. Such statements often contain words such as “expect,” “may,” “can,” “estimate,” “intend,” “anticipate,” “will,” “potential,” “projected" and other similar words. Forward-looking statements address matters that are, to varying degrees, uncertain, such as forecasts or expectations regarding the deployment of, or anticipated benefits of, SLB’s new technologies and partnerships; statements about goals, plans and projections with respect to sustainability and environmental matters; forecasts or expectations regarding energy transition and global climate change; and improvements in operating procedures and technology. These statements are subject to risks and uncertainties, including, but not limited to, the inability to achieve net-negative carbon emissions goals; the inability to recognize intended benefits of SLB’s strategies, initiatives or partnerships; legislative and regulatory initiatives addressing environmental concerns, including initiatives addressing the impact of global climate change; the timing or receipt of regulatory approvals and permits; and other risks and uncertainties detailed in SLB’s most recent Forms 10-K, 10-Q and 8-K filed with or furnished to the U.S. Securities and Exchange Commission. If one or more of these or other risks or uncertainties materialize (or the consequences of such a development changes), or should underlying assumptions prove incorrect, actual outcomes may vary materially from those reflected in our forward-looking statements. The forward-looking statements speak only as of the date of this press release, and SLB disclaims any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250825924465/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wolters Kluwer lancerer Capego Practice Management – en cloud-løsning til moderne revisions- og bogføringsfirmaer1.9.2025 01:00:00 CEST | Pressemeddelelse
Dette cloudbaserede softwaresystem samler alt, hvad revisions- og bogføringsfirmaer har brug for, i én kraftfuld, forbundet platform, der er fuldt integreret med Capego-produktserien Wolters Kluwer Tax & Accounting Danmark er stolte af at kunne annoncere lanceringen af Capego Practice Management, en cloud-baseret løsning designet til at give revisions- og bogføringsfirmaer smartere og mere integrerede arbejdsgange. Capego-pakken samler nu alt, hvad firmaer har brug for – fra kundedata og opgavestyring til fakturering og compliance – i ét sikkert, skalerbart system. "Capego Practice Management repræsenterer et stort fremskridt i måden, hvorpå revisions- og bogføringsfirmaer kan operere i dagens digitale verden," siger Stefan Wahle, vicepræsident og general manager, Wolters Kluwer Tax & Accounting, Europa Region Nord. "Ved at samle kundesamarbejde, opgavestyring, compliance og fakturering i én fuldt integreret platform hjælper vi firmaer med at arbejde smartere, overholde reglerne og lev
Wolters Kluwer Launches Capego Practice Management - A Cloud Solution for Modern Tax and Accounting Firms1.9.2025 01:00:00 CEST | Press release
This cloud-based software system brings together everything tax and accounting firms need into one powerful, connected platform that’s fully integrated with the Capego suite of products Wolters Kluwer Tax & Accounting Denmark is proud to announce the launch of Capego Practice Management, a cloud-native solution designed to empower tax and accounting firms with smarter, more connected workflows. The Capego suite now brings together everything firms need—from client data and task management to invoicing and compliance—into one secure, scalable system. “Capego Practice Management represents a major leap forward in how tax and accounting firms can operate in today’s digital-first world,” said Stefan Wahle, Vice President & General Manager, Wolters Kluwer Tax & Accounting, Europe Region North. “By bringing together client collaboration, task management, compliance, and invoicing into one fully integrated platform, we’re helping firms work smarter, stay compliant, and deliver exceptional ser
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 11:15:00 CEST | Press release
− Sustained Benefit of Vutrisiran Across Mortality, Cardiovascular Events, Quality of Life and Cardiac Biomarkers Observed Through Up to 48 Months, Including 12 Months from the Ongoing Open-Label Extension, Reinforce Potential as First-Line Treatment for ATTR-CM –− Vutrisiran, which Delivers Rapid Knockdown of Transthyretin, Reduced the Risk of Composite of All-Cause Mortality or First Cardiovascular Event by 37% in the Overall Population and 42% in the Monotherapy Group During the Same Period – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Card
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 08:30:00 CEST | Press release
DEWA will organise the exhibition from 30 September to 2 October 2025 Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial i
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release
Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom